Avalo Therapeutics, Inc. current report, 13 February 2020

SEC Filing Summary: Cerecor Inc. (8-K)

Business Context and Reporting Period

This Form 8-K was filed by Cerecor Inc. on February 14, 2020, reporting an event that occurred on February 13, 2020. The registrant is a Delaware corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the Nasdaq Capital Market under the symbol "CERC". The company is classified as an Emerging Growth Company.

Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.

Material Changes

The material change reported is the resignation of Peter Greenleaf from the Board of Directors, effective immediately on February 13, 2020. The filing states that the resignation was due to Mr. Greenleaf's other board commitments and was not related to any disagreement with the Company regarding its operations, policies, or practices.

Guidance, Outlook, and Risks

The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies are disclosed in this report other than the standard disclosure regarding the director's departure.

Key Facts for Investor Verification

  • Verify the current composition of the Board of Directors following the resignation of Peter Greenleaf.
  • Confirm whether the Board has initiated a search for a replacement director.
  • Review subsequent filings to determine if the resignation impacts any ongoing corporate governance or strategic initiatives.